Quest Diagnostics SEC filings, summarized
We read every Quest Diagnostics 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track DGX in your inbox
Add Quest Diagnostics to your watchlist — free, every morning.
Recent filings
Quest Diagnostics raises 2026 revenue and EPS guidance after strong third quarter
Quest Diagnostics reported third-quarter 2026 revenue of $3.097 billion, up 10.0% from a year earlier, with GAAP diluted EPS of $2.78 and adjusted diluted…
Quest Diagnostics Reports Unauthorized Access to Quanum LSM System
Quest Diagnostics said on October 21, 2026, that an unauthorized party accessed its Quanum LSM system, which clients use to order tests and view results,…
Quest Diagnostics Executive Catherine Doherty to Retire in July 2027
Catherine T. Doherty will retire from Quest Diagnostics in July 2027 and, effective November 1, 2026, will become an executive vice president overseeing…
Quest Diagnostics CEO Davis J. E. sells $2.4M in stock
Davis J. E., CEO and president and a director of Quest Diagnostics, sold 10,000 shares of common stock on Sept. 1 at $242.72 per share, for approximately…
Quest Diagnostics general counsel sells $5.5M in stock
Michael E. Prevoznik, Quest Diagnostics’ SVP and General Counsel, sold 16,010 shares at $242.88 each for approximately $3.89 million, leaving him with…
Quest Diagnostics Reports Q2 Growth and Raises 2026 Guidance
Quest Diagnostics reported second-quarter 2026 revenue of $3.04 billion, up 10.2% year over year, with reported diluted EPS of $2.84 and adjusted diluted…
Quest Diagnostics ($DGX) filed a Form 8‑K on Mar 12, 2026 — Item 9.01 lists exhibits: Press release dated…
Quest Diagnostics ($DGX) filed a Form 8‑K on Mar 12, 2026 — Item 9.01 lists exhibits: Press release dated Mar 12, 2026 (Ex.99.1) and Inline XBRL cover page…
Quest Diagnostics ($DGX) disclosed (Reg FD) that Mr.
Quest Diagnostics ($DGX) disclosed (Reg FD) that Mr. Wentworth was elected to its Board of Directors. Press release is attached as Exhibit 99.1 and…
On Mar 9, 2026 Quest Diagnostics ($DGX) added Timothy Wentworth, former CEO of Walgreens Boots Alliance,…
On Mar 9, 2026 Quest Diagnostics ($DGX) added Timothy Wentworth, former CEO of Walgreens Boots Alliance, to its Board. He was appointed to the Compensation…
Quest Diagnostics ($DGX) filed a Form 8-K on Feb 10, 2026 attaching a press release with Q4 & FY 2025…
Quest Diagnostics ($DGX) filed a Form 8-K on Feb 10, 2026 attaching a press release with Q4 & FY 2025 results for the quarter and full year ended Dec 31,…
Quest Diagnostics ($DGX) Board of Directors authorized an additional $1.0B of common stock repurchases…
Quest Diagnostics ($DGX) Board of Directors authorized an additional $1.0B of common stock repurchases under its ongoing program — announced Feb 10, 2026.…
Quest Diagnostics ($DGX) filed an 8‑K (Item 2.02) on Feb 10, 2026 announcing Q4 and full‑year results for…
Quest Diagnostics ($DGX) filed an 8‑K (Item 2.02) on Feb 10, 2026 announcing Q4 and full‑year results for the period ended Dec 31, 2025; press release…
Quest Diagnostics ($DGX) filed a Form 8‑K on Jan 12, 2026 — Item 9.01 lists Exhibit 99.1: Presentation…
Quest Diagnostics ($DGX) filed a Form 8‑K on Jan 12, 2026 — Item 9.01 lists Exhibit 99.1: Presentation dated Jan 12, 2026, and Exhibit 104: cover page in…
Quest Diagnostics ($DGX) will present on strategy, performance and market trends at the 44th Annual J.P.
Quest Diagnostics ($DGX) will present on strategy, performance and market trends at the 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026 —…
Quest Diagnostics filed a Form 8‑K on 2026‑01‑12: Item 2.02 says results of operations and financial…
Quest Diagnostics filed a Form 8‑K on 2026‑01‑12: Item 2.02 says results of operations and financial condition info are incorporated by reference from Item…